Chinese guidelines for the diagnosis and treatment of childhood-onset systemic lupus erythematosus

title: Chinese guidelines for the diagnosis and treatment of childhood-onset systemic lupus erythematosus
Edition: Original
Classification: Standard guideline
Field: Diagnosis and Management
Countries and regions: China
Guide users: The target implementation agencies include medical institutions and health authorities that provide health care services to the target population. The target end users of this guideline are medical workers in rheumatology, pediatric and laboratory.
Evidence classification method: The GRADE approach will be used to assess the quality of evidence for each clinical question. According to the GRADE approach, the quality of evidence can be classified as high, moderate, low, and very low and the results will be drafted and presented in the form of evidence summary table. Randomized controlled trials are regarded as high-quality evidence while observational studies as low-quality evidence. Then initial quality can be downgraded for five reasons (study limitations, consistency of effect, imprecision, indirectness, and publication bias) and upgraded for three reasons (large magnitude of effect, dose-response relation and plausible confounders or biases).
Development unit: Group of Immunology of Society of Pediatrics from Chinese Medical Association and editorial office of The Chinese Journal of Pediatrics
Registration time: 2020-07-31
Registration number: IPGRP-2020CN105
Purpose of the guideline: To develop a patient-based, clinical problem-oriented, evidence-based and high-quality guideline, the Guideline Working Group will strictly follow the standards and procedures of international organizations, select optimal specific problems in clinical practice of cSLE, systematically search, assess and syntheses evidence, consider patients’ value and preferences by combing with the clinical practice of China and experience from multidisciplinary experts. The development of this guideline will help to standardize the management of cSLE in China, improve the prognosis of patients, reduce medical costs and economic burden, and improve the overall level of medical services.